Five up-and-coming University of Otago scholars, described as ''shining examples'' of academic talent, have been recognised through Early Career Awards for Distinction in Research. Recipients of the university's latest annual early career awards are Dr Karen Brouneus, National Centre for Peace and Conflict Studies; Dr Lyndie Foster Page, dentistry; Dr Carla Meledandri, chemistry; Dr Virginia Toy, geology; and Dr Suetonia Palmer, of the Christchurch campus. Their research spans the psychological aspects of peace-building, improving young people's oral health, developing nanoscale materials for nanomedicine, as well as structural geology and seismic processes, and improving kidney disease treatment. Announcing the awards, the deputy vice-chancellor, research and enterprise, Prof Richard Blaikie said the five scholars were ''shining examples'' of the depth and breadth of talent among the university's up-and-coming researchers. Their work was already creating ''new knowledge that underpins improvements in health, technology, social wellbeing and our understanding of environmental processes'' . The five academics were well-placed to be among Otago's future research leaders, Prof Blaikie said. Each award winner receives a $5000 grant to use for research and scholarly development, and becomes a member of the university's O-Zone group of early-to-mid career researchers. Dr Brouneus is a recipient of Otago's New Supervisor … Continue reading →

Washington, June 10 (ANI): Liver transplantation is the mainstay of treatment for patients with end-stage liver disease, but a new research from the Icahn School of Medicine at Mount Sinai has suggested that it may one day become possible to regenerate a liver using cell therapy in patients with liver disease. Investigators discovered that a human embryonic stem cell can be differentiated into a previously unknown liver progenitor cell, an early offspring of a stem cell, and produce mature and functional liver cells. "The discovery of the novel progenitor represents a fundamental advance in this field and potentially to the liver regeneration field using cell therapy," said the study's senior author, Valerie Gouon-Evans, PharmD, PhD, Assistant Professor, in the Department of Developmental and Regenerative Biology, Black Family Stem Cell Institute, at the Icahn School of Medicine at Mount Sinai. "Until now, liver transplantation has been the most successful treatment for people with liver failure, but we have a drastic shortage of organs. This discovery may help circumvent that problem," In conjunction with the laboratory of Matthew J. Evans, PhD, from the Department of Microbiology at Icahn School of Medicine at Mount Sinai, investigators demonstrated the functionality of the liver cells … Continue reading →

NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - Jun 10, 2013) - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has successfully treated the eighth patient in its ongoing Phase IIa ALS clinical trial at the Hadassah Medical Center in Jerusalem, Israel, thus completing treatment of the second of three cohorts. Enrollment of the final group of four patients has also been completed, and the company expects to conclude treatment of these patients by the end of the third quarter of this year. In this Phase IIa dose-escalating trial, currently underway at Hadassah under the direction of Principal Investigator Professor Dimitrios Karussis, 12 ALS patients are receiving combined intramuscular (IM) and intrathecal (IT) administration of NurOwn cells, in three cohorts, with increasing doses. The study participants will be monitored for six months following transplantation. About BrainStorm Cell Therapeutics, Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with … Continue reading →

CANCER sufferer Kate Blackhurst is recovering at home after undergoing a revolutionary stem cell transplant to try to beat the disease. The 20-year-old, picturedright, was offered the treatment on the NHS after being struck down with cancer twice in three years. The latest treatment saw some of Kate's healthy stem cells frozen by experts at The Queen Elizabeth Hospital, in Birmingham. She then received chemotherapy five times more powerful than a normal dose to try to kill the cancerous cells as the frozen stem cells were put back in her body during almost four weeks of treatment last month. BlueSky CVs Print voucher BlueSky CVs consultants can help you with some simple techniques that will help you feel confident and comfortable in your next interview - helping the real you to shine through Terms: 50% up front payment and 50% on completion Contact: 01538 710408 Valid until: Wednesday, June 12 2013 See the article here: The Sentinel commented Staffordshire cancer sufferer undergoes revolutionary treatment … Continue reading →